HCPCS Level II
Q2055
Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Codes near Q2055
These sit next to Q2055 in the CMS Level II file. All Q codes
- Q2049Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg
- Q2050Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
- Q2052Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)
- Q2053Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2054Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2056Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2057Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2058Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
- Q3001Radioelements for brachytherapy, any type, each
- Q3014Telehealth originating site facility fee
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 59572-0515-01 | Abecma | Celgene Corporation | 1 |
| 59572-0515-02 | Abecma | Celgene Corporation | 1 |
| 59572-0515-03 | Abecma | Celgene Corporation | 1 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.